



SCIFINITI
PUBLISHING

Cancer Research and Therapy Connect

ISSN: 3105-3629

Vol. 2, 2026



Open Access Peer-Reviewed Journal Specialized in
Targeted Cancer Therapy and Immunotherapy

www.scifiniti.com

Cancer Research and Therapy Connect

A Journal Specialized in Targeted Cancer Therapy and Immunotherapy

Volume: 2, 2026

Subject Categories

Targeted Cancer Therapy

Immunotherapy

Precision Oncology

Target Audience

Cancer Research and Therapy Connect provides a platform for researchers, clinicians, and practitioners to share their findings, discuss challenges, and explore new frontiers in the fight against cancer through immunological approaches.



Professor Eyad Elkord

Editor-in-Chief

Director, Centre of Excellence for Oncology and Immunology, Academy of Life and Natural Sciences, Xi'an Jiaotong-Liverpool University, Suzhou, China

Message from EiC

As we enter 2026 and launch a new volume of Targeted Cancer Therapy Connect, we reaffirm our commitment to serving as a trusted, peer-reviewed platform for researchers and clinicians to share high-quality advances in targeted cancer therapy, immunotherapy, and precision oncology. The journal welcomes innovative basic, translational, and clinical research that deepens understanding of tumour biology and tumour-immune interactions, and accelerates meaningful progress toward improved patient care. In 2026, we will place stronger emphasis on thematic/Special Issues and will be inviting researchers throughout the year to contribute and propose timely themes.

Aims and Scope

Cancer Research and Therapy Connect is a peer-reviewed, open-access journal dedicated to advancing the full spectrum of cancer research, from fundamental biology to therapeutic innovation. The journal publishes innovative research that deepens understanding of the molecular, cellular, and immunological mechanisms driving cancer initiation, progression, and treatment response. Our goal is to accelerate the translation of scientific discoveries into effective, patient-centered cancer care.

Key Topics

Cancer Biology and Mechanisms – Oncogenesis, tumor suppressor biology, signaling pathways, tumor microenvironment, metastasis, and the discovery and validation of novel therapeutic targets.

Therapeutics and Drug Development – Small-molecule inhibitors, monoclonal antibodies, antibody–drug conjugates (ADCs), peptide- and protein-based drugs, next-generation modalities such as PROTACs, chemotherapy, radiotherapy, and other emerging treatment approaches.

Immunotherapy and Precision Oncology – Immune checkpoint inhibitors, bispecific antibodies, CAR-T and TCR-based therapies, cancer vaccines, and biomarker-guided treatment strategies.

Drug Resistance and Combination Therapy – Mechanisms of resistance and rational combination regimens integrating targeted, cytotoxic, and immune-based agents.

Clinical and Translational Research – Clinical trials across all therapeutic modalities, pharmacogenomics, predictive and prognostic biomarkers and diagnostics — including screening biomarkers, liquid biopsy, molecular diagnostics, imaging technologies, and early detection approaches supporting timely clinical intervention.

Technological and Methodological Advances – CRISPR and gene-editing tools, single-cell omics, proteomics, nanomedicine, and computational or AI-driven approaches for target discovery, diagnostics, and drug development.

